Cancer name Non Small Cell Lung Cancer
Cancer Type NSCLC
Immunotherapy type Immune Checkpoint Therapy
Treatment NA
Drugstatus NA
Drugbank ID NA
Checkpoints PD-1
Signature Type Gene
Signature JAK2
Official Symbol JAK2
Mode of action MU_R_GAIN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental patients
Description Gene expression analysis revealed thatJAK2gain is associated withsignificantly elevated PD-L1 expression (p=0.012, two-sidedt-test; Fig. 3) whileJAK2loss is associated withsignificantly reduced PD-L1 expression (p= 0.0039,two-sidedt-test; Fig. 3).JAK2loss due to either non-sense mutation or deletion had similar effect on PD-L1expression (Additional file 2: Figure S1). We hypothesizethatJAK2activating mutations such as p.V617F couldbe associated with increased PD-L1 expression andtherefore sensitize the tumor to anti-PD1 immunother-apy.
PMID 29082853
Title Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications